Progress in the pharmacodynamics of antibi-otics

Abstract

CLC Number:

R978

REN Shao-Hua, HU Hua-Chen. Progress in the pharmacodynamics of antibi-otics[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(1): 86-89.

1 Dagan R, KlugmanKP, Craug WA, et al.Evidence to support the rationale that bacterial eradication in respiratory tract infec-tion is an important aim of antimicrobial therapy[J]. J Antimi-crob Chemother, 2001;47:129-40
2 Jacobs MR, Weinberg W.Evidence-based guidelines for treat-ment of bacterial respiratory tract infections in the era of antibi-otic resistance[J]. Manag Care Interface, 2001;14:66-7
3 Burgess DS.Pharmacodynamic principles of antimicrobial thera-py in the prevention of resistance[J]. Chest, 1999;115(3s): 19s-23s
4 Gonzales R, Bartlett JG, Besser RE, et al.Principles of appro-priate antibiotic use for treatment of acute respiratory tract infec-tions in adults:background, specific aims, and methods[J]. Ann InternMed, 2001;134:479-86
5 Wise R, Honeybourne D.Pharmacokinetics and pharmacody-namics of fluoroquinolones in the respiratory tract[J]. Eur Respir J, 1999;14:221-9
6 Yates RR.New intervention strategiesfor reducing antibiotic re-sistance[J]. Chest, 1999;115(3s):24s-7s
7 Weber DJ, Raasch R, Rutala WA.Nosocomial infections in the ICU :the growing importance of antibiotic-resistant pathogens [J]. Chest, 1999;115(3s):34s-41s
8 Tessier PR, Nicolau DP, Onyeji CO, et al.Pharmacodynamics of intermittent -and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model[J]. Chemotherapy, 1999;45:284-95
9 Dulaney-Lopez AM, Rodriguez JC, Lopez-Samblas AM, et al. Limiting cefotaxime pediatric dosing to adult standards:a phar-macokinetic simulation study[J]. Int J Clin Pharmacol Ther, 1999;37:269-74
10 Morris RG, Sallustio BC, Vinks AA, et al.Some international approaches to aminoglycoside monitoring in the extended dosing interval era[J]. Ther Drug Monit, 1999;21:379-88
11 Kashuba AD, Nafziger AN, Drusano GL, et al.Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria[J]. Antimicrob Agents Chemother, 1999;43:623-9
12 Andes DR, Craig WA.Pharmacokinetics and pharmacodynam-ics of antibiotics in meningitis[J]. Infect Dis Clin North Am, 1999;13:595-618

[1]	DU Caifeng, MAO Yunan, GAO Jia, WANG Juan, LI Xiaoye, TIAN Junsheng, LIU Hongqi. Research on serum metabolic markers of menopausal syndrome based on 1H-NMR metabolomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 961-968.
[2]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[3]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[4]	MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
[5]	WANG Kun, XU Peipei, ZHOU Lanlan, LU Sheng. Mechanism of neuroprotective effect of ginsenoside Rg1 regulating Epac1/Rap1 signaling pathway in rats with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 721-727.
[6]	LI Shixu, LI Linyun, WANG Xin, LI Ke, BIAN Hua. Effects of Ginkgo biloba extract on renal injury in rats with experimental renal failure through miR-145/FOXO1 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 728-735.
[7]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[8]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[9]	QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
[10]	QIN Wenxiu, XU Junfeng, YANG Ting, WANG Pingfei. Research progress on signaling pathway of tanshinoneIIA in treatment of nerve injury after ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 705-713.
[11]	LIU Xiumei, GUO Qianqian, FANG Yuan, CHEN Nan, QI Qi. Pharmaceutical care of patients with antithrombotic therapy after transjugular intrahepatic portal shunt [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 556-560.
[12]	FENG Zhuangzhuang, SONG Ruiping, DOU Pengcheng, CHEN Xinyi, ZUO Jiaojiao, SHU Jin. Effect of Zhiwei Fuwei Pills on autophagy in gastric antrum tissue of rats with precancerous lesions of gastric cancer based on mTOR/Beclin1/LC3 signaling axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 361-370.
[13]	LIU Tong, XU Jiaming, WANG Jinhuo, YIN Lei, CHEN Yongquan, GUO Jianrong. Changes of anesthetic drug concentration in plasma during isolation of autologous blood with acute isovolumic hemodilution and its influence on anesthetic effect after reinfusion [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 413-418.
[14]	ZHANG Qiang, ZHENG Huajun, LI Quan. Research progress on the treatment of autism spectrum disorders based on gut microbiota intervention [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 475-480.
[15]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.

Progress in the pharmacodynamics of antibi-otics

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments